Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy
Direct stimulation of the antitumor activity of immune system through checkpoint inhibitors (ICIs) has demonstrated efficacy in the treatment of different cancer types. The activity of these antibodies takes place in the immunological synapse blocking the binding of the negative immunoregulatory pro...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-07-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1445952 |
id |
doaj-c53ae6b0c9ec468b89e1d19b29b52fc6 |
---|---|
record_format |
Article |
spelling |
doaj-c53ae6b0c9ec468b89e1d19b29b52fc62020-11-25T03:04:25ZengTaylor & Francis GroupOncoImmunology2162-402X2018-07-017710.1080/2162402X.2018.14459521445952Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapyM. Xipell0I. Victoria1V. Hoffmann2J. Villarreal3A. García-Herrera4O. Reig5L. Rodas6M. Blasco7E. Poch8B. Mellado9L. F. Quintana10Hospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaHospital Clínic, IDIBAPS, Universitat de BarcelonaDirect stimulation of the antitumor activity of immune system through checkpoint inhibitors (ICIs) has demonstrated efficacy in the treatment of different cancer types. The activity of these antibodies takes place in the immunological synapse blocking the binding of the negative immunoregulatory proteins, thus leading to the finalization of the immune response. Despite having a favorable toxicity profile, its mechanism of action impedes the negative regulation of the immune activity which can potentially favor autoimmune attacks to normal tissues. Renal toxicity has been described in several ICI but not with atezolizumab, an IgG1 monoclonal antibody targeting PD-L1 (programmed death ligand 1), approved by FDA as a second-line therapy for advanced urothelial carcinoma. Here we present a patient with a single kidney and metastatic renal cell carcinoma treated with atezolizumab and bevacizumab combination, with biopsy-proven acute interstitial nephritis, who had a complete resolution of renal dysfunction after steroid therapy.http://dx.doi.org/10.1080/2162402X.2018.1445952atezolizumabimmune check-point inhibitorspd-l1tubulointerstitial nephritis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
M. Xipell I. Victoria V. Hoffmann J. Villarreal A. García-Herrera O. Reig L. Rodas M. Blasco E. Poch B. Mellado L. F. Quintana |
spellingShingle |
M. Xipell I. Victoria V. Hoffmann J. Villarreal A. García-Herrera O. Reig L. Rodas M. Blasco E. Poch B. Mellado L. F. Quintana Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy OncoImmunology atezolizumab immune check-point inhibitors pd-l1 tubulointerstitial nephritis |
author_facet |
M. Xipell I. Victoria V. Hoffmann J. Villarreal A. García-Herrera O. Reig L. Rodas M. Blasco E. Poch B. Mellado L. F. Quintana |
author_sort |
M. Xipell |
title |
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy |
title_short |
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy |
title_full |
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy |
title_fullStr |
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy |
title_full_unstemmed |
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy |
title_sort |
acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy |
publisher |
Taylor & Francis Group |
series |
OncoImmunology |
issn |
2162-402X |
publishDate |
2018-07-01 |
description |
Direct stimulation of the antitumor activity of immune system through checkpoint inhibitors (ICIs) has demonstrated efficacy in the treatment of different cancer types. The activity of these antibodies takes place in the immunological synapse blocking the binding of the negative immunoregulatory proteins, thus leading to the finalization of the immune response. Despite having a favorable toxicity profile, its mechanism of action impedes the negative regulation of the immune activity which can potentially favor autoimmune attacks to normal tissues. Renal toxicity has been described in several ICI but not with atezolizumab, an IgG1 monoclonal antibody targeting PD-L1 (programmed death ligand 1), approved by FDA as a second-line therapy for advanced urothelial carcinoma. Here we present a patient with a single kidney and metastatic renal cell carcinoma treated with atezolizumab and bevacizumab combination, with biopsy-proven acute interstitial nephritis, who had a complete resolution of renal dysfunction after steroid therapy. |
topic |
atezolizumab immune check-point inhibitors pd-l1 tubulointerstitial nephritis |
url |
http://dx.doi.org/10.1080/2162402X.2018.1445952 |
work_keys_str_mv |
AT mxipell acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT ivictoria acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT vhoffmann acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT jvillarreal acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT agarciaherrera acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT oreig acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT lrodas acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT mblasco acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT epoch acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT bmellado acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy AT lfquintana acutetubulointerstitialnephritisassociatedwithatezolizumabanantiprogrammeddeathligand1pdl1antibodytherapy |
_version_ |
1724681930239115264 |